Drugs Containing Excipient (Inactive Ingredient) SODIUM BENZOATE

Branded drugs containing SODIUM BENZOATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	HALCION	triazolam	0009-0017	SODIUM BENZOATE
PHARMACIA & UPJOHN COMPANY LLC	XANAX	alprazolam	0009-0029	SODIUM BENZOATE
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	SODIUM BENZOATE

Generic drugs containing SODIUM BENZOATE excipient

Company	Ingredient	NDC	Excipient
Pharmacia & Upjohn Company LLC	triazolam	0009-0017	SODIUM BENZOATE
PHARMACIA & UPJOHN COMPANY LLC	alprazolam	0009-0029	SODIUM BENZOATE
Viatris Specialty LLC	mesalamine	0037-0022	SODIUM BENZOATE

Sodium Benzoate Market Dynamics, Pharmaceutical Demand, Pricing, and Financial Outlook

Last updated: September 20, 2026

Sodium benzoate is a low-cost, high-volume preservative excipient used primarily in oral liquid medicines, nutritional products, cosmetics, and food. Its pharmaceutical market is stable rather than high-growth. Revenue expansion depends more on formulation outsourcing, liquid-dose demand, regulatory compliance, and supply-chain pricing than on new drug approvals.

The ingredient has no meaningful Orange Book exclusivity, no biosimilar exposure, and limited standalone patent protection. Commercial risk is concentrated in raw-material costs, supplier qualification, regulatory specifications, and substitution by potassium sorbate, parabens, benzoic acid, or preservative-free packaging.

What is sodium benzoate used for in pharmaceuticals?

Sodium benzoate is the sodium salt of benzoic acid, identified by CAS No. 532-32-1. In pharmaceutical products, it is used mainly as an antimicrobial preservative and, in some formulations, as a pH-control or solubility-supporting excipient.

Primary pharmaceutical applications

Application	Typical role	Commercial relevance
Oral syrups and solutions	Antimicrobial preservative	Largest pharmaceutical use
Pediatric liquid medicines	Preservative in multidose containers	Important because liquid formulations are more contamination-prone
Oral electrolyte and nutritional products	Preservation and formulation support	Linked to hospital, retail, and nutrition demand
Topical and cosmetic products	Microbial control	Often competes with parabens and sorbates
Veterinary medicines	Preservative in liquid dosage forms	Demand follows animal-health formulations
Solid-dose medicines	Limited direct use	Less important than in aqueous products

Preservative performance is pH-dependent. Sodium benzoate is most effective in acidic formulations because the undissociated form of benzoic acid has stronger antimicrobial activity. Formulators therefore evaluate sodium benzoate alongside pH, water activity, container closure, preservative efficacy testing, and microbial-risk controls.

The excipient does not function as an active pharmaceutical ingredient. It has no independent therapeutic exclusivity and normally does not determine a product’s regulatory exclusivity period.

What is the regulatory status of pharmaceutical-grade sodium benzoate?

Sodium benzoate is an established food and pharmaceutical excipient with broad regulatory acceptance, subject to use-level limits, product specifications, and jurisdiction-specific labeling requirements.

United States

The U.S. Food and Drug Administration lists sodium benzoate in the Inactive Ingredient Database for multiple dosage forms and routes. The substance is also recognized as generally regarded as safe for specified food uses under 21 C.F.R. § 184.1733 (U.S. Food and Drug Administration, n.d.-a).

Drug manufacturers remain responsible for demonstrating that the selected concentration is suitable for the formulation and route of administration. FDA inactive-ingredient precedent does not create approval rights for a specific supplier or formulation.

European Union

Sodium benzoate is authorized as food additive E211 under the European Union food-additive framework. Pharmaceutical use is assessed through applicable European Pharmacopoeia requirements, national or centralized product approvals, and the quality documentation submitted for the finished medicine (European Parliament & Council, 2008).

Global safety position

The Joint FAO/WHO Expert Committee on Food Additives established a group acceptable daily intake for benzoates of 0-5 mg/kg body weight, expressed as benzoic acid equivalents (FAO/WHO, 2017). The limit is most relevant to cumulative exposure from food, medicines, and other products.

Pediatric formulations require particular attention to exposure, concentration, dosing frequency, and the overall excipient profile. Sodium benzoate is not automatically unsuitable for pediatric use, but manufacturers must assess the amount delivered per dose and the population receiving the medicine.

How large is the sodium benzoate market?

Public market reports generally combine sodium benzoate across food, pharmaceutical, personal-care, industrial, and feed applications. They also use different definitions of market size, geographic scope, and product grade. No widely accepted public dataset isolates pharmaceutical-grade sodium benzoate revenue.

The market is best understood as a mature commodity excipient segment with a smaller, higher-specification pharmaceutical component.

Demand structure

Food preservation is the largest demand pool. Pharmaceutical demand is smaller but more specification-sensitive because suppliers must support:

• Pharmacopeial or customer specifications
• Impurity and residual-solvent controls
• Traceability and change-control systems
• Audit readiness
• Consistent particle size and assay
• Documentation for regulatory submissions
• Stability and microbial-performance data

Pharmaceutical-grade demand can generate better margins than food-grade material, but qualification cycles are longer and volume is lower. Customers often maintain approved supplier lists, making replacement slower than in industrial markets.

Main demand drivers

Driver	Effect on sodium benzoate demand
Growth in oral liquid medicines	Positive
Pediatric and geriatric formulations	Positive
Contract manufacturing and private-label medicines	Positive
Expansion of emerging-market healthcare	Positive
Shift to preservative-free single-dose packaging	Negative
Reformulation toward potassium sorbate or parabens	Mixed
Higher regulatory scrutiny of excipient exposure	Negative or neutral
Growth in ready-to-drink nutrition products	Positive but primarily food-sector

Published commercial forecasts often project low- to mid-single-digit growth for the broader sodium benzoate market, but those estimates should not be treated as audited pharmaceutical revenue forecasts. The pharmaceutical segment is likely to grow more slowly than some food and beverage applications because it is mature and has multiple formulation alternatives.

What is the financial trajectory for sodium benzoate suppliers?

The financial trajectory is typically volume-driven, with profitability affected by raw materials, energy, logistics, plant utilization, and grade mix.

Revenue model

Sodium benzoate is generally sold through:

1. Direct supply contracts with large food, pharmaceutical, and consumer-product manufacturers.
2. Regional distributors serving smaller formulation customers.
3. Specialty excipient distributors supplying documentation and smaller packaging.
4. Contract manufacturing and private-label channels.

The product is usually sold as a standardized chemical rather than a branded technology platform. Supplier revenue therefore depends on shipped volume, contract pricing, geographic coverage, and qualification retention.

Cost structure

The main cost variables are:

• Benzoic acid availability and pricing
• Sodium hydroxide costs
• Energy consumption
• Labor and plant overhead
• Packaging
• Ocean freight and inland transport
• Environmental compliance
• Quality-control testing
• Inventory and working-capital requirements

A simplified production chain is:

Benzoic acid + sodium hydroxide → sodium benzoate + water

Feedstock integration can improve cost control. Suppliers with access to benzoic acid production, efficient crystallization and drying operations, and regional warehouses are better positioned than distributors exposed to spot purchases and freight volatility.

Financial outlook by period

Period	Expected market condition	Financial implication
2024-2025	Stable demand with variable logistics and input costs	Margin volatility rather than rapid volume growth
2026-2028	Gradual demand expansion in liquid medicines and processed foods	Moderate revenue growth
Longer term	Mature market with formulation substitution	Pricing discipline and operational efficiency become more important

Large chemical companies may not disclose sodium benzoate as a separate reporting line. For example, LANXESS reports broader business segments rather than standalone sodium benzoate revenue. Financial analysis therefore requires supplier-level estimates, shipment data, tender information, and distributor pricing rather than public segment accounts.

Which companies supply pharmaceutical-grade sodium benzoate?

The competitive field includes integrated chemical producers, specialty excipient companies, and distributors. Supplier participation varies by region and product grade.

Relevant supplier categories

Supplier type	Competitive advantage
Integrated chemical producers	Feedstock access, scale, lower unit cost
Specialty excipient manufacturers	Documentation, smaller batch sizes, customer service
Global distributors	Local inventory, regulatory support, multi-product relationships
Regional producers	Shorter delivery routes and price competitiveness
Custom manufacturers	Customer-specific specifications and packaging

LANXESS is a significant named supplier through the Emerald Kalama Chemical business, which produces benzoic-acid derivatives and related preservative products. Dr. Paul Lohmann, Spectrum Chemical, Avantor, and regional chemical suppliers also participate in pharmaceutical and laboratory supply channels, although product availability and grade status vary by market.

A supplier’s inclusion in a catalog does not establish that every listed grade is suitable for an approved medicinal product. Pharmaceutical buyers evaluate the specific manufacturing site, quality agreement, certificate of analysis, audit history, and change-notification process.

What patents protect sodium benzoate?

Sodium benzoate itself has little meaningful exclusivity protection as a pharmaceutical excipient. The molecule is an old, well-characterized salt and is not protected by a commercially relevant foundational composition patent.

Patent exposure by category

Patent category	Risk level	Explanation
Basic composition patent	Very low	The compound is longstanding and widely used
Manufacturing-process patent	Low to moderate	Process claims may cover crystallization, purification, or particle control
Formulation patent	Moderate for specific products	Claims may cover preservative systems, pH, dosage form, or packaging
Method-of-use patent	Low for the excipient itself	Drug patents may claim a therapeutic use involving a formulation that contains sodium benzoate
Packaging patent	Product-specific	Relevant to preservative-free or multidose delivery systems
Supplier-specific patent	Low	Documentation and quality systems are usually not patent barriers

Any active patent risk normally attaches to the finished drug formulation, preservative combination, delivery device, or manufacturing process. It does not generally prevent another supplier from manufacturing sodium benzoate that meets applicable specifications.

What is the Orange Book status of sodium benzoate?

Sodium benzoate is not itself an Orange Book-listed drug product. The FDA Orange Book lists approved drug products and, where applicable, patents and regulatory exclusivities associated with those products. It does not create an Orange Book patent estate for a commodity excipient.

Paragraph IV challenges

There is no standalone Paragraph IV pathway for sodium benzoate as an excipient. Paragraph IV certifications apply to abbreviated new drug applications that challenge patents listed for a reference drug. A generic manufacturer could face Paragraph IV issues if a finished drug containing sodium benzoate has listed formulation, method-of-use, or other patents.

Biosimilar risk

Biosimilar risk is not applicable to sodium benzoate. It is a small-molecule chemical, not a biologic active ingredient. Sodium benzoate can appear in biologic formulations, but its presence does not make the excipient subject to biosimilar competition.

What formulation patents and litigation affect sodium benzoate?

Formulation patents may claim a specific preservative system, pH range, concentration, dosage form, or container configuration. These patents are usually owned by the drug manufacturer and concern the finished product rather than the excipient supply market.

Potentially relevant claim types include:

• A liquid medicine containing sodium benzoate at a defined concentration
• A combination of sodium benzoate with another antimicrobial
• A pH-controlled formulation
• A stable pediatric formulation
• A multidose container with a preservative system
• A process that improves stability or reduces degradation
• A method for preventing microbial growth in a specific product

There is no broadly recognized, industry-defining patent litigation campaign centered on sodium benzoate supply. Litigation exposure is generally product-specific and may arise from ANDA filings, formulation patents, trade secrets, manufacturing contracts, or regulatory disputes.

No major licensing transaction is publicly associated with sodium benzoate as a standalone excipient. Licensing economics are more likely to arise in finished pharmaceutical products, proprietary preservative systems, or contract manufacturing arrangements.

How does sodium benzoate compare with competing preservatives?

Excipient	Main advantages	Main limitations
Sodium benzoate	Low cost, water solubility, broad regulatory history	Best performance at acidic pH; exposure scrutiny
Potassium sorbate	Effective in acidic products, widely used in food and medicines	pH dependence and possible taste considerations
Methylparaben and propylparaben	Broad preservative history and strong activity	Solubility limits; consumer and formulation preferences
Benzoic acid	Active preservative form and established use	Lower water solubility than sodium benzoate
Phenoxyethanol	Useful in topical and cosmetic products	Less common in oral pharmaceutical liquids
Benzyl alcohol	Preservative and solvent functions	Pediatric and neonatal exposure limitations
Preservative-free packaging	Avoids preservative exposure	Higher packaging cost and multidose limitations

Sodium benzoate has its strongest commercial position in acidic, aqueous, multidose products where low cost and water solubility matter. Its position is weaker in neutral-pH products, preservative-sensitive pediatric products, and markets moving toward single-dose or preservative-free delivery.

What generic launch risks exist for sodium benzoate-containing medicines?

Generic entry risk depends on the finished medicine’s patent and regulatory profile, not on sodium benzoate ownership.

Generic launch scenarios

1. Simple oral liquid: Low formulation complexity, with competition focused on price, supply reliability, and bioequivalence or comparative quality requirements.
2. Pediatric liquid with proprietary flavor or preservative system: Moderate risk if formulation patents or regulatory exclusivities are active.
3. Drug-device combination: Higher risk where the container, dosing mechanism, or delivery system is protected.
4. Preservative-free alternative: Competitive disruption if the generic uses unit-dose packaging or a different microbial-control strategy.
5. Complex sterile product: Sodium benzoate is generally not the central preservative strategy; other excipient and manufacturing barriers dominate.

For excipient suppliers, generic entry can increase sodium benzoate volumes because multiple manufacturers may launch the same product. It can also compress selling prices and increase customer concentration risk.

How strong is the sodium benzoate patent estate?

The standalone patent estate is weak because the compound is old, widely available, and manufactured by multiple suppliers. The defensible commercial assets are operational rather than patent-based.

Practical sources of supplier advantage

• Consistent pharmaceutical-grade quality
• Approved manufacturing sites
• Reliable batch-to-batch assay
• Global regulatory documentation
• Dual-region production or warehousing
• Low impurity profile
• Customer-specific packaging
• Proven change-control performance
• Long-term supply agreements
• Qualification history with major drug manufacturers

These factors can create switching costs without creating legal exclusivity. A buyer may be able to purchase technically equivalent material from another supplier, but regulatory requalification, stability work, and supply-chain risk can delay substitution.

What geographic markets drive sodium benzoate growth?

Asia-Pacific is the largest manufacturing and consumption region for many commodity preservatives, supported by chemical production capacity, food processing, generic pharmaceuticals, and export infrastructure. North America and Europe remain important higher-compliance markets with demand for validated pharmaceutical and food grades.

Regional dynamics

Region	Market characteristics
China	Large production base, export capacity, price competition
India	Expanding generic pharmaceutical and formulation manufacturing
North America	Mature demand, strong documentation and supplier qualification
Europe	High regulatory compliance, specialty and premium-grade demand
Latin America	Food, beverage, and generic-drug growth
Middle East and Africa	Import-dependent markets with distributor-led supply

Geographic diversification matters because freight disruption, trade restrictions, energy prices, and local regulatory changes can alter delivered cost more than chemical conversion cost.

Key Takeaways

• Sodium benzoate is a mature, low-cost pharmaceutical excipient used mainly as an antimicrobial preservative in oral liquids.
• Food and beverage demand is larger than pharmaceutical demand, while pharmaceutical-grade material earns value from documentation and qualification.
• Public companies rarely disclose sodium benzoate revenue separately, limiting precise financial modeling.
• Growth is likely to be moderate and volume-led, with profitability driven by feedstock, energy, freight, and grade mix.
• The compound has no meaningful standalone Orange Book, Paragraph IV, biosimilar, or foundational patent exposure.
• Formulation and method-of-use patents may affect specific finished medicines containing sodium benzoate.
• Potassium sorbate, parabens, benzyl alcohol, phenoxyethanol, and preservative-free packaging are the main competitive alternatives.
• The strongest supplier advantages are quality systems, manufacturing reliability, regulatory support, and customer qualification, not patent exclusivity.
• Generic launches can increase demand while reducing pricing power for suppliers.
• The principal commercial risks are substitution, regulatory exposure in sensitive populations, supply-chain concentration, and commodity price volatility.

FAQs About Sodium Benzoate Pharmaceutical Markets

Is sodium benzoate an active pharmaceutical ingredient?

No. Sodium benzoate is generally an inactive pharmaceutical ingredient used as a preservative or formulation aid.

Can sodium benzoate be used in pediatric medicines?

Yes, but the concentration and total exposure must be evaluated for the intended population, dosage regimen, and route of administration.

Does sodium benzoate require a drug master file?

A drug master file or equivalent supplier package may be used when a manufacturer needs confidential information about production and controls. The requirement depends on the finished-product sponsor, jurisdiction, and regulatory strategy.

Is pharmaceutical-grade sodium benzoate interchangeable between suppliers?

Not automatically. Substitution may require assessment of specifications, impurities, particle properties, manufacturing site, stability impact, supplier qualification, and regulatory change-control obligations.

What is the largest threat to sodium benzoate demand?

The largest structural threat is substitution in formulations that move to potassium sorbate, parabens, alternative preservatives, single-dose packaging, or preservative-free delivery. Cost inflation and supply disruption are more immediate financial risks.

References

1. European Parliament & Council. (2008). Regulation (EC) No. 1333/2008 on food additives. Official Journal of the European Union.

2. Food and Agriculture Organization of the United Nations & World Health Organization. (2017). Evaluation of certain food additives: Eighty-third report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization.

3. U.S. Food and Drug Administration. (n.d.-a). 21 C.F.R. § 184.1733, sodium benzoate.

4. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.